×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Events
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Kidney Cancer

Ryan McDonald
Data from a phase 2 study presented during the 2020 ASCO Virtual Scientific Program demonstrated that Avastin (bevacizumab) in combination with Tarceva (erlotinib) was well tolerated and produced encouraging clinical outcomes in patients with advanced hereditary leiomyomatosis and renal cell carcinoma or sporadic papillary renal cell carcinoma.
 
Ryan McDonald
Data from a phase 3 study presented at the 2020 ASCO Virtual Scientific Program showed that treatment with savolitinib demonstrated encouraging efficacy and an improved safety over standard-of-care Sutent (sunitinib) in patients with MET-driven papillary renal cell carcinoma.
 
Ryan McDonald
A roundup of the latest news and updates for patients with Renal Cell Carcinoma from CURE®.
 
Amy Paturel
A variety of novel treatments, including immunotherapies, extend life for patients with advanced kidney cancer.
Kidney Cancer Association
Getting kidney cancer treatment during the COVID-19 pandemic.
Kidney Cancer Association
Kidney cancer positives that might come from this pandemic.
Kidney Cancer Association
How kidney cancer affects the risks of coronavirus.
Kidney Cancer Association
A message from the KCA’s CEO and President about COVID-19.
Kidney Cancer Association
Kidney cancer changed how Tracie saw her world.
Kidney Cancer Association
On his motorcycle, Stewy rides for kidney cancer.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×